Other Events ·
Aquestive Therapeutics presents investor deck highlighting $90.3M cash, Anaphylm PDUFA date of March 16, 2027
AQSTAquestive Therapeutics, Inc.
Aquestive Therapeutics furnished an investor presentation to institutional investors and analysts on November 5, 2026. The company reported a cash position of $90.3 million as of September 30, 2026, with potential access to up to $75 million under a strategic funding agreement with RTW Investments and an additional $20 million from Oaktree Capital Management, both contingent on FDA approval of its lead asset Anaphylm (dibutepinephrine). The presentation confirmed the Prescription Drug User Fee Act (PDUFA) goal date for Anaphylm is March 16, 2027, following FDA acceptance of a Class 2 resubmission. Aquestive also outlined launch readiness planning and discussed its AdrenaVerse pipeline, including AQST-108 for atopic dermatitis. The company operates in the biopharmaceutical industry, developing innovative drug delivery technologies and medicines.